Duopharma Biotech Berhad reported robust growth for Q3 FY2024, with revenue reaching RM208.73 million, pushing cumulative revenue for the year to RM620.02 million—a 15.4% increase year-on-year. The company also saw a cumulative profit before tax (PBT) increase of 11.3% and profit after tax (PAT) rise by 7.7%. This growth was largely driven by higher sales, especially in the public health sector, which balanced rising costs from the new K3 facility and increased financing expenses.
Duopharma Biotech – Growth
The company’s strategic focus on internal efficiencies and cost management continues to pay off. With the Malaysian government’s recent 10% healthcare budget increase, Duopharma sees a positive outlook for demand in public health supplies.
Additionally, two Duopharma subsidiaries received five new Letters of Offer to supply products to government facilities until December 2026, adding an estimated RM87.66 million to the order book. Duopharma also issued an interim dividend of 1.0 sen per share, totaling RM9.62 million for shareholders.
Table of Contents
Read More News on Business News Malaysia
Follow us on:
Read More News #latestmalaysia
Read More News on Business News Malaysia


Leave a Reply
You must be logged in to post a comment.